CLARITY TIMI 28

OBJECTIVE: To assess the efficacy and safety of adding clopidogrel to a standard fibrinolytic regimen that includes aspirin.

View/Download
_______________________________________________________________________________

  1. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. Sabatine MS, McCabe CH, Gibson CM, Cannon CP. Am Heart J 2005;149:227-33.
    | Abstract | Request Reprints |

  2. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. Sabatine MS, Cannon CP, Gibson CM, et al. N Engl J Med 2005;352:1179-89.
    | Abstract | Request Reprints |

  3. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. Sabatine MS, Cannon CP, Gibson CM, et al. JAMA 2005;294:1224-32.
    | Abstract | Request Reprints |

  4. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Sabatine MS, Morrow DA, Montalescot G, et al. Circulation 2005;112:3846-54.
    | Abstract | Request Reprints |

  5. Improved Findings on Late Angiography Are Associated with Lower Rates of New Q-waves in Patients Receiving Fibrinolysis for ST Elevation Myocardial Infarction - Results From CLARITY-TIMI 28.Scirica BM, Sabatine MS, Murphy SA, Kirtane A, Aroesty J, Cannon CP, Gibson CM. Circulation 2005; 112 (17 Suppl II) :II-693.
    | Request Reprints |

  6. Correlates and outcomes associated with ST segment resolution after fibrinolytic therapy. Results from the ECG CLARITY - TIMI 28 substudy.Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E. Circulation 2005;112:II:486.
    | Request Reprints |

  7. Differences between streptokinase and fibrin-specific fibrinolytic therapy when co-administered with adjunctive clopidogrel: A CLARITY-TIMI 28 substudy. Kirtane AJ, Sabatine MS, Aroesty JM, Murphy SA, Scirica BM, Pinto DS, Southard M, Stein E, Cannon CP, Braunwald E, Gibson CM. Circulation 2005;112:II:567.
    | Request Reprints |

  8. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. Scirica BM, Sabatine MS, Morrow DA, et al. J Am Coll Cardiol 2006;48:37-42.
    | Abstract | Request Reprints |

  9. Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. Kirtane AJ, Vafai JJ, Murphy SA, et al. Eur Heart J 2006;27:2040-5.
    | Abstract | Request Reprints |

  10. Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). Gibson CM, Ly HQ, Murphy SA, et al. Am J Cardiol 2006;98:761-3.
    | Abstract | Request Reprints |

  11. Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis in CLARITY-TIMI 28. Ahmed S, Sabatine MS, Cannon CP, Murphy SA, Braunwald E, Gibson CM. J Am Coll Cardiol 2006;47:159A.
    | Request Reprints |

  12. Association of TIMI risk score and extent of coronary artery disease in patients with ST-elevation myocardial infarction: CLARITY-TIMI 28 substudy.O’Donoghue M, Sabatine MS, Wiviott SD, Murphy SA, McCabe CH, Cannon CP, Braunwald E, Gibson CM. J Am Coll Cardiol 2006;47:222A.
    | Request Reprints |

  13. Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 Trial.Verheugt FW, Montalescot G, Sabatine MS, Soulat L, Lambert Y, Lapostolle F, Adgey J, Cannon CP. J Thromb Thrombolysis 2006;22:161- 4.
    | Request Reprints |

  14. Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. McLean DS, Sabatine MS, Guo W, McCabe CH, Cannon CP. J Thromb Thrombolysis 2007;24:85-91.
    | Abstract | Request Reprints |

  15. Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. Gibson CM, Pride YB, Buros JL, et al. J Am Coll Cardiol 2008;51:546-51.
    | Abstract | Request Reprints |

  16. Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). Pinto DS, Kirtane AJ, Pride YB, et al. Am J Cardiol 2008;101:303-7.
    | Abstract | Request Reprints |

  17. Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy. Gibson CM, Pride YB, Buros JL, et al. Am J Cardiol 2008;101:1232-8.
    | Abstract | Request Reprints |

  18. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. Gibson CM, Murphy SA, Pride YB, et al. Am Heart J 2008;155:133-9.
    | Abstract | Request Reprints |

  19. Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. O'Donoghue M, Morrow DA, Cannon CP, et al. Eur Heart J 2008;29:984-91.
    | Abstract | Request Reprints |

  20. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Sabatine MS, Hamdalla HN, Mehta SR, et al. Am Heart J 2008;155:910-7.
    | Abstract | Request Reprints |

  21. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Sabatine MS, Morrow DA, Higgins LJ, et al. Circulation 2008;117:1936-44.
    | Abstract | Request Reprints |

 

 

 

Home | Trials | Core Laboratories | Services | Publications | Education | Funding | Contact Us |

© 2009 All Rights Reserved TIMI Study Group